Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Venlafaxine hydrochloride [USAN:USP]
RN: 99300-78-4
UNII: 7D7RX5A8MO
InChIKey: QYRYFNHXARDNFZ-UHFFFAOYSA-N

Note

  • A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.

Molecular Formula

  • C17-H27-N-O2.Cl-H

Molecular Weight

  • 313.8662
 

Classification Codes

  • Antidepressant
  • Antidepressive Agents
  • Antidepressive Agents, Second-Generation
  • Central Nervous System Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Membrane Transport Modulators
  • Neurotransmitter Agents
  • Neurotransmitter Uptake Inhibitors
  • Psychotropic Drugs
  • Serotonin and Noradrenaline Reuptake Inhibitors

Names and Synonyms

Name of Substance

  • Venlafaxine hydrochloride [USAN:USP]

MeSH Heading

  • Venlafaxine Hydrochloride

Synonyms

  • (+-)-1-(alpha-((Dimethylamino)methyl)-p-methoxybenzyl)cyclohexanol hydrochloride
  • 1-(2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol hydrochloride
  • Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
  • Dobupal
  • Effexor
  • Effexor XR
  • Sila-venlafaxine
  • Trevilor
  • UNII-7D7RX5A8MO
  • Vandral
  • Venlafaxine HCl
  • Venlafaxine hydrochloride
  • Wy 45030
  • Wy-45,030
  • Wy-45030

Systematic Name

  • Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride

Registry Numbers

CAS Registry Number

  • 99300-78-4

FDA UNII

  • 7D7RX5A8MO

Related Registry Number

  • 93413-69-5 (Parent)

System Generated Number

  • 0099300784

Molecular Formulas

Molecular Formula

  • C17-H27-N-O2.Cl-H

Molecular Formula Fragments

  • C17-H27-N-O2
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

InChI=1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

InChIKey

QYRYFNHXARDNFZ-UHFFFAOYSA-N

Smiles

Cl.COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo oral 1071ug/kg (1.071mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE

SKIN AND APPENDAGES (SKIN): SWEATING: OTHER
Journal of Toxicology, Clinical Toxicology. Vol. 35, Pg. 211, 1997.
man TDLo oral 32mg/kg/9W-I (32mg/kg) BEHAVIORAL: HEADACHE

BEHAVIORAL: WITHDRAWAL
Medical Journal of Australia. Vol. 169, Pg. 91, 1998.
women LDLo oral 168mg/kg (168mg/kg) BEHAVIORAL: COMA

CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Medical Journal of Australia. Vol. 169, Pg. 445, 1998.
women LDLo oral 235mg/kg/12D- (235mg/kg) GASTROINTESTINAL: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA

LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)"
Journal of Analytical Toxicology. Vol. 20, Pg. 266, 1996.
women TDLo oral 94500ug/kg/9W (94.5mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

SKIN AND APPENDAGES (SKIN): SWEATING: OTHER
Annals of Pharmacotherpy. Vol. 33, Pg. 1009, 1999.
women TDLo oral 315mg/kg/30W- (315mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: WITHDRAWAL

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Medical Journal of Australia. Vol. 169, Pg. 91, 1998.
women TDLo oral 360mg/kg/17W- (360mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

BEHAVIORAL: WITHDRAWAL

SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
Medical Journal of Australia. Vol. 169, Pg. 91, 1998.